This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miettinen, H. E. Articles by Kontula, K. Search for Related Content PubMed PubMed Citation Articles by Miettinen, H. E. Articles by Kontula, K.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:3021-3032.)
© 1997 American Heart Association, Inc.

Articles

Apolipoprotein A-I_FIN (Leu159Arg) Mutation Affects Lecithin

Cholesterol Acyltransferase Activation and Subclass Distribution of HDL but Not Cholesterol Efflux From Fibroblasts

Helena E. Miettinen; Matti Jauhiainen; Helena Gylling; Sonja Ehnholm; Ari Palomäki; Tatu A. Miettinen; ; Kimmo Kontula

From the Department of Medicine, University of Helsinki, Helsinki, Finland (H.E.M., H.G., T.A.M, K.K); the Department of Biochemistry, National Public Health Institute, Helsinki, Finland (M.J., S.E.); and the Department of Cardiology, Central Hospital of Hämeenlinna, Finland (A.P.).

Correspondence to Helena E. Miettinen, MD, Department of Medicine, University of Helsinki, Meilahti Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland. E-mail Helena.Miettinen{at}helsinki.fi

Abstract We showed earlier that the apolipoprotein A-I Leu159Arg mutation (apoA-I_Fin) results in dominantly inherited hypoalphalipoproteinemia. In the present study we investigated the effect of the apoA-I_Fin mutation on lipoprotein profile, apoA-I kinetics, lecithin:cholesterol acyltransferase (LCAT) activation, and cholesterol efflux in vitro. Carriers (n=9) of the apoA-I_Fin mutation exhibited several lipoprotein abnormalities. The serum HDL cholesterol level was diminished to 20% of normal, and nondenaturing gradient gel electrophoresis of HDL showed disappearance of particles at the 9.0- to 12-nm size range (HDL₂-type) and the presence of small 7.8- to 8.9-nm (mostly HDL₃-type) particles only. HDL₃-type particles from both the mutation carriers and nonaffected family members were similarly converted to large, HDL₂-type particles by phospholipid transfer protein in vitro. Studies on apoA-I kinetics in four affected subjects favored accelerated catabolism of apoA-I. Experiments with reconstituted proteoliposomes showed that the capacity of apoA-I_Fin protein to activate LCAT was reduced to 40% of that of the wild-type apoA-I. The impact of the apoA-I_Fin protein on cholesterol efflux was examined in vitro using [³H]cholesterol-loaded human fibroblasts and three different cholesterol acceptors: (1) total HDL, (2) total apoA-I combined with phospholipid, and (3) apoA-I isoform (apoA-I_Fin or wild-type apoA-I isoform 1) combined with phospholipid. ApoA-I_Fin did not impair phospholipid binding or cholesterol efflux from fibroblasts to any of the acceptors used. Only one of the nine apoA-I_Fin carriers appears to have evidence of clinically manifested atherosclerosis. In conclusion, although the apoA-I_Fin mutation does not alter the properties of apoA-I involved in promotion of cholesterol efflux, its ability to activate LCAT in vitro is defective. In vivo, apoA-I_Fin was found to be associated with several lipoprotein composition rearrangements and increased catabolism of apoA-I.

Key Words: reverse cholesterol transport • HDL • apolipoprotein A-I kinetics • coronary artery disease • mutation

This article has been cited by other articles:

				J. S. Owen, M. S. Bharadwaj, M. J. Thomas, S. Bhat, M. P. Samuel, and M. G. Sorci-Thomas Ratio determination of plasma wild-type and L159R apoA-I using mass spectrometry: tools for studying apoA-IFin J. Lipid Res., January 1, 2007; 48(1): 226 - 234. [Abstract] [Full Text] [PDF]

				P. G. Yancey, B. F. Asztalos, N. Stettler, D. Piccoli, D. L. Williams, M. A. Connelly, and G. H. Rothblat SR-BI- and ABCA1-mediated cholesterol efflux to serum from patients with Alagille syndrome J. Lipid Res., September 1, 2004; 45(9): 1724 - 1732. [Abstract] [Full Text] [PDF]

				S. Bhat, M. Zabalawi, M. C. Willingham, G. S. Shelness, M. J. Thomas, and M. G. Sorci-Thomas Quality control in the apoA-I secretory pathway: deletion of apoA-I helix 6 leads to the formation of cytosolic phospholipid inclusions J. Lipid Res., July 1, 2004; 45(7): 1207 - 1220. [Abstract] [Full Text] [PDF]

				D. Sviridov, A. Hoang, W. Huang, and J. Sasaki Structure-function studies of apoA-I variants: site-directed mutagenesis and natural mutations J. Lipid Res., August 1, 2002; 43(8): 1283 - 1292. [Abstract] [Full Text] [PDF]

				P. G. Frank and Y. L. Marcel Apolipoprotein A-I: structure;-function relationships J. Lipid Res., June 1, 2000; 41(6): 853 - 872. [Abstract] [Full Text]

				M. G. Sorci-Thomas, M. Thomas, L. Curtiss, and M. Landrum Single Repeat Deletion in ApoA-I Blocks Cholesterol Esterification and Results in Rapid Catabolism of Delta 6 and Wild-type ApoA-I in Transgenic Mice J. Biol. Chem., April 14, 2000; 275(16): 12156 - 12163. [Abstract] [Full Text] [PDF]

				P. Holvoet, B. De Geest, S. Van Linthout, M. Lox, S. Danloy, K. Raes, and D. Collen The Arg123-Tyr166 Central Domain of Human ApoAI Is Critical for Lecithin:Cholesterol Acyltransferase-Induced Hyperalphalipoproteinemia and HDL Remodeling in Transgenic Mice Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 459 - 466. [Abstract] [Full Text] [PDF]

				W. Huang, J. Sasaki, A. Matsunaga, H. Han, W. Li, T. Koga, M. Kugi, S. Ando, and K. Arakawa A Single Amino Acid Deletion in the Carboxy Terminal of Apolipoprotein A-I Impairs Lipid Binding and Cellular Interaction Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 210 - 216. [Abstract] [Full Text] [PDF]

				U. Daum, T. P. Leren, C. Langer, A. Chirazi, P. Cullen, P. H. Pritchard, G. Assmann, and A. von Eckardstein Multiple dysfunctions of two apolipoprotein A-I variants, apoA-I(R160L)Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers J. Lipid Res., March 1, 1999; 40(3): 486 - 494. [Abstract] [Full Text]

				H.E. Miettinen, H. Gylling, J. Tenhunen, J. Virtamo, M. Jauhiainen, J.K. Huttunen, I. Kantola, T.A. Miettinen, and K. Kontula Molecular Genetic Study of Finns With Hypoalphalipoproteinemia and Hyperalphalipoproteinemia : A Novel Gly230Arg Mutation (LCATFin) of Lecithin:Cholesterol Acyltransferase (LCAT) Accounts for 5% of Cases With Very Low Serum HDL Cholesterol Levels Arterioscler Thromb Vasc Biol, April 1, 1998; 18(4): 591 - 598. [Abstract] [Full Text] [PDF]

				D. C. McManus, B. R. Scott, V. Franklin, D. L. Sparks, and Y. L. Marcel Proteolytic Degradation and Impaired Secretion of an Apolipoprotein A-I Mutant Associated with Dominantly Inherited Hypoalphalipoproteinemia J. Biol. Chem., June 8, 2001; 276(24): 21292 - 21302. [Abstract] [Full Text] [PDF]